Health Technology · Pharmaceuticals: Major · NSE: SYNCOMF · data 2026-10-09
Syncom Formulation (India) Ltd.
Health check: Strong (8.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹23.28
Market cap
₹2,217 cr
P/E
25.6
P/B
—
ROE
20.2%
ROCE
16.3%
Debt / equity
0
Dividend yield
0.42%
1-year return
35.3%
52-week high
₹27.49
52-week low
₹10.21
Operating margin
16.3%
Growth
| Revenue (last 12 months) | ₹498 cr |
| Net profit (last 12 months) | ₹86 cr |
| Sales growth, 3 years (yearly) | 29.4% |
| Profit growth, 3 years (yearly) | 56.2% |
Similar companies
Dishman Carbogen Amcis Ltd. (DCAL) · Venus Remedies Limited (VENUSREM) · Sai Parenterals Limited (SAIPARENT) · Sakar Healthcare Ltd (SAKAR) · Indoco Remedies Limited (INDOCO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SYNCOMF in NSE Scanner →